MacroGenics, Inc. (NASDAQ:MGNX – Get Free Report) has received an average recommendation of “Hold” from the ten ratings firms that are presently covering the firm, Marketbeat.com reports. Seven equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $8.11.
Several equities analysts recently issued reports on the stock. HC Wainwright restated a “neutral” rating and issued a $4.00 target price on shares of MacroGenics in a report on Wednesday, August 21st. BMO Capital Markets dropped their target price on shares of MacroGenics from $8.00 to $5.00 and set a “market perform” rating on the stock in a report on Wednesday, August 7th. JMP Securities dropped their target price on shares of MacroGenics from $16.00 to $8.00 and set a “market outperform” rating on the stock in a report on Wednesday, July 31st. B. Riley lowered shares of MacroGenics from a “buy” rating to a “neutral” rating and dropped their target price for the company from $18.00 to $5.00 in a report on Wednesday, July 31st. Finally, BTIG Research lowered shares of MacroGenics from a “buy” rating to a “neutral” rating in a report on Thursday, August 1st.
Check Out Our Latest Stock Report on MGNX
Hedge Funds Weigh In On MacroGenics
MacroGenics Price Performance
Shares of MacroGenics stock opened at $3.61 on Friday. MacroGenics has a twelve month low of $3.14 and a twelve month high of $21.88. The company’s fifty day moving average is $4.02 and its 200 day moving average is $8.76.
MacroGenics (NASDAQ:MGNX – Get Free Report) last issued its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.89) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.42). MacroGenics had a negative return on equity of 146.01% and a negative net margin of 332.47%. The business had revenue of $10.80 million during the quarter, compared to the consensus estimate of $24.14 million. Analysts expect that MacroGenics will post -1.72 EPS for the current year.
MacroGenics Company Profile
MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.
See Also
- Five stocks we like better than MacroGenics
- The How And Why of Investing in Oil Stocks
- 3 Leveraged ETFs to Multiply Returns
- Investing In Preferred Stock vs. Common Stock
- A Tale of Two Titans: Unveiling the Value in Baidu and JD.com
- What is an Earnings Surprise?
- Is the AI-Capable iPhone 16 the Start of a Sales Super-Cycle?
Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.